YAHONG MEDICAL (688176.SH) released its semi-annual report for 2024 on August 28. In the first half of 2024, the company achieved revenue of 80.4934 million yuan, with the second quarter reaching 56.1739 million yuan, an increase of 130.98% compared to the previous quarter. In addition, the company is actively promoting the launch of two core products. The new drug application for APL-1702 has been accepted and the company is actively progressing with its market approval process. It is expected to become the world's first non-surgical treatment for high-grade squamous intraepithelial lesions of the cervix. APL-1706 has successfully passed the verification by the Center for Food and Drug Inspection (CFDI) of the National Medical Products Administration, and is expected to obtain market approval by the end of June 2025. This product is currently the only approved contrast agent for diagnosing or performing surgery for bladder cancer.
亚虹医药(688176.SH)：2024年Q2营收环比增长130.98% 核心产品上市稳步推进
Yuhong Pharmaceutical (688176.SH): The revenue in Q2 of 2024 increased by 130.98% month-on-month, and the core products are steadily progressing to market.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated